4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Neuroimaging and End Stage Renal Disease (NESRD)

Neuroimaging and End Stage Renal Disease (NESRD)

Study Description
Brief Summary:
Brain impairment is one of the common complications of end-stage renal disease (ESRD). The patients always present with various cerebrovascular diseases, cognitive impairment and sensorimotor abnormalities, with morbidity over 40%. However, the risk factors and the neural mechanisms of brain injury in ESRD is still unclear. Identifying the risk factors and finding objective and reliable biomarkers of brain impairment in the process of ESRD is an important clinical problem. At the same time, to find the neural mechanisms of brain damage in ESRD is a serious scientific problem. Neuroimaging techniques based on multi-modal magnetic resonance image (MRI) can detect the structural and functional brain abnormalities objectively and sensitively, especially for those without obvious clinical symptoms. Through the deep analysis of brain MRI data, it is helpful for studying the neural mechanisms of brain damage in ESRD in the perspective from brain science. In addition, the accumulation of uremic toxins is supposed to play an essential role in the brain impairment of ESRD. The metabolomics is a useful method in detecting the uremic toxins with different molecular weights. In this study, the investigators will collect the brain MRI, serum metabolomics and cognitive assessment data before the dialysis initiation, and then will make prospective longitudinal observation of changes of brain impairment during the dialysis. Thus, combining analysis of neuroimaging and metabolomics will provide more information for finding the risk factors and imaging diagnostic markers of brain impairment in ESRD. It will also helpful for explaining the underlying mechanisms of brain impairment in ESRD, providing an objective basis for clinical diagnosis and prediction of the prognosis.

Condition or disease Intervention/treatment
End Stage Renal Disease Device: magnetic resonance image (MRI)

Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 192 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Combination of Neuroimaging and Metabolomics of Brain Impairment in Patients With End-stage Renal Disease: a Multi-center Prospective Cohort Study
Actual Study Start Date : July 1, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021
Arms and Interventions
Group/Cohort Intervention/treatment
ESRD group Device: magnetic resonance image (MRI)
serum metabolomics
Other Name: serum

Control group Device: magnetic resonance image (MRI)
serum metabolomics
Other Name: serum

Outcome Measures
Primary Outcome Measures :
  1. Change from baseline brain structure measures at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The changes of brain volume (mm3) are evaluated by structural MRI

  2. Change from baseline brain function measures at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The changes of brain functional connectivity intensity are evaluated by functional MRI


Secondary Outcome Measures :
  1. Changes from baseline cognitive condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The cognitive condition is assessed by Montreal cognitive assessment (MoCA). The MoCA assesses several cognitive domains: 1) visuospatial and executive abilities are assessed using a trail-making test B (1 point), clock-drawing task (3 points) and a cube copy (1 point); 2) naming is assessed with low-familiarity animals (3 points); 3) the short-term memory (5 points) involves two learning trials of five nouns; 4) attention are evaluated using a sustained attention task (1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each); 5) language is assessed using a repetition of two syntactically complex sentences (2 points), and the verbal fluency task (1 point); 6) orientation to time and place is evaluated by asking the subject for the date and the city (6 points). The scale ranges is from 0 to 30, and score of 26 or over is considered to be normal. Subscales are summed to compute a total score, and higher values represent a better outcome.

  2. Changes from baseline depression condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The affective complaints are assessed by Beck depression inventory (BDI). The BDI is a 21-question multiple-choice self-report inventory in the past week, for measuring the severity of depression. The BDI is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Each question had a set of at least four possible responses, ranging in intensity: (0) I do not feel sad; (1) I feel sad; (2) I am sad all the time and I can't snap out of it; (3) I am so sad or unhappy that I can't stand it. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is summed to be compared to a key to determine the depression's severity. The scale ranges is from 0 to 63, and the higher total scores indicate more severe depressive symptoms.

  3. Changes from baseline anxiety condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The affective complaints are assessed by Beck anxiety inventory (BAI). The BAI is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety in children and adults. The questions used in this measure ask about common symptoms of anxiety that the subject has had during the past week (including the day you take it) (such as numbness and tingling, sweating not due to heat, and fear of the worst happening). The BAI contains 21 questions, each answer being scored on a scale value of 1 (not at all) ,2 (mild), 3 (moderate), to 4 (severely). The scale ranges is from 21 to 84 , and higher total scores indicate more severe anxiety symptoms.

  4. Changes from baseline serum metabolomics at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The serum metabolomics are conducted by liquid Chromatograph Mass Spectrometer (LC-MS), mainly including the molecules of uremic toxins.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All of the patients of ESRD group are in-patients and out-patients in the nephrology department from three research centers. The subjects of control group are recruited from community.
Criteria

Inclusion Criteria:

  • Diagnosis with end stage renal disease before dialysis initiation
  • Chronic renal failure
  • Chronic renal failure
  • 18-55 years old
  • Right handedness

Exclusion Criteria:

  • Concurrent severe infection
  • With other severe diseases
  • History of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc.
  • History of alcohol dependence and drug abuse
  • History of brain operation
  • Loss of vision or hearing
  • Psychotropic medication in three months
  • Contraindication of MRI examination, such as metal implants and claustrophobia, and other reasons that cannot cooperate with MRI examination
  • Cerebrovascular diseases which can be detected from conventional MR images, including the size of cerebral hemorrhage over 10 mm, infarction over 20 mm, subarachnoid hemorrhage, subdural hemorrhage and extradural hemorrhage.
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Ming Zhang, PhD 0086-18991232265 zmmri@163.com
Contact: Shaohui Ma, MD 0086-15029215781 sh_ma@163.com

Locations
Layout table for location information
China, Shaanxi
First Affiliated Hospital of Xian Jiaotong University Recruiting
Xian, Shaanxi, China, 710061
Contact: Ming Zhang, PhD    0086-18991232265    zmmri@163.com   
Contact: Shaohui Ma, MD    0086-15029215781    zhangming01@xjtu.edu.cn   
Sponsors and Collaborators
First Affiliated Hospital Xi'an Jiaotong University
NO.215 Hospital of Shaanxi Nuclear Industry
Baoji Zhongxin Hospital
Taihe Hospital
Investigators
Layout table for investigator information
Principal Investigator: Ming Zhang, PhD First Affiliated Hospital of Xian Jiaotong University
Tracking Information
First Submitted Date April 26, 2019
First Posted Date May 23, 2019
Last Update Posted Date August 14, 2019
Actual Study Start Date July 1, 2019
Estimated Primary Completion Date December 31, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 21, 2019)
  • Change from baseline brain structure measures at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The changes of brain volume (mm3) are evaluated by structural MRI
  • Change from baseline brain function measures at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The changes of brain functional connectivity intensity are evaluated by functional MRI
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: August 11, 2019)
  • Changes from baseline cognitive condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The cognitive condition is assessed by Montreal cognitive assessment (MoCA). The MoCA assesses several cognitive domains: 1) visuospatial and executive abilities are assessed using a trail-making test B (1 point), clock-drawing task (3 points) and a cube copy (1 point); 2) naming is assessed with low-familiarity animals (3 points); 3) the short-term memory (5 points) involves two learning trials of five nouns; 4) attention are evaluated using a sustained attention task (1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each); 5) language is assessed using a repetition of two syntactically complex sentences (2 points), and the verbal fluency task (1 point); 6) orientation to time and place is evaluated by asking the subject for the date and the city (6 points). The scale ranges is from 0 to 30, and score of 26 or over is considered to be normal. Subscales are summed to compute a total score, and higher values represent a better outcome.
  • Changes from baseline depression condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The affective complaints are assessed by Beck depression inventory (BDI). The BDI is a 21-question multiple-choice self-report inventory in the past week, for measuring the severity of depression. The BDI is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Each question had a set of at least four possible responses, ranging in intensity: (0) I do not feel sad; (1) I feel sad; (2) I am sad all the time and I can't snap out of it; (3) I am so sad or unhappy that I can't stand it. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is summed to be compared to a key to determine the depression's severity. The scale ranges is from 0 to 63, and the higher total scores indicate more severe depressive symptoms.
  • Changes from baseline anxiety condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The affective complaints are assessed by Beck anxiety inventory (BAI). The BAI is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety in children and adults. The questions used in this measure ask about common symptoms of anxiety that the subject has had during the past week (including the day you take it) (such as numbness and tingling, sweating not due to heat, and fear of the worst happening). The BAI contains 21 questions, each answer being scored on a scale value of 1 (not at all) ,2 (mild), 3 (moderate), to 4 (severely). The scale ranges is from 21 to 84 , and higher total scores indicate more severe anxiety symptoms.
  • Changes from baseline serum metabolomics at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The serum metabolomics are conducted by liquid Chromatograph Mass Spectrometer (LC-MS), mainly including the molecules of uremic toxins.
Original Secondary Outcome Measures
 (submitted: May 21, 2019)
  • Changes from baseline cognitive condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The cognitive condition are assessed by Montreal cognitive assessment (score).
  • Changes from baseline depression condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The affective complaints are assessed by Beck depression inventory (score).
  • Changes from baseline anxiety condition at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The affective complaints are assessed by Beck anxiety inventory (score).
  • Changes from baseline serum metabolomics at 3 months and 12months [ Time Frame: baseline (before dialysis initiation), hemodialysis for 3 months and 12 months ]
    The serum metabolomics are conducted by liquid Chromatograph Mass Spectrometer (LC-MS), mainly including the molecules of uremic toxins.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Neuroimaging and End Stage Renal Disease
Official Title Combination of Neuroimaging and Metabolomics of Brain Impairment in Patients With End-stage Renal Disease: a Multi-center Prospective Cohort Study
Brief Summary Brain impairment is one of the common complications of end-stage renal disease (ESRD). The patients always present with various cerebrovascular diseases, cognitive impairment and sensorimotor abnormalities, with morbidity over 40%. However, the risk factors and the neural mechanisms of brain injury in ESRD is still unclear. Identifying the risk factors and finding objective and reliable biomarkers of brain impairment in the process of ESRD is an important clinical problem. At the same time, to find the neural mechanisms of brain damage in ESRD is a serious scientific problem. Neuroimaging techniques based on multi-modal magnetic resonance image (MRI) can detect the structural and functional brain abnormalities objectively and sensitively, especially for those without obvious clinical symptoms. Through the deep analysis of brain MRI data, it is helpful for studying the neural mechanisms of brain damage in ESRD in the perspective from brain science. In addition, the accumulation of uremic toxins is supposed to play an essential role in the brain impairment of ESRD. The metabolomics is a useful method in detecting the uremic toxins with different molecular weights. In this study, the investigators will collect the brain MRI, serum metabolomics and cognitive assessment data before the dialysis initiation, and then will make prospective longitudinal observation of changes of brain impairment during the dialysis. Thus, combining analysis of neuroimaging and metabolomics will provide more information for finding the risk factors and imaging diagnostic markers of brain impairment in ESRD. It will also helpful for explaining the underlying mechanisms of brain impairment in ESRD, providing an objective basis for clinical diagnosis and prediction of the prognosis.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population All of the patients of ESRD group are in-patients and out-patients in the nephrology department from three research centers. The subjects of control group are recruited from community.
Condition End Stage Renal Disease
Intervention Device: magnetic resonance image (MRI)
serum metabolomics
Other Name: serum
Study Groups/Cohorts
  • ESRD group
    Intervention: Device: magnetic resonance image (MRI)
  • Control group
    Intervention: Device: magnetic resonance image (MRI)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: May 21, 2019)
192
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 31, 2021
Estimated Primary Completion Date December 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Diagnosis with end stage renal disease before dialysis initiation
  • Chronic renal failure
  • Chronic renal failure
  • 18-55 years old
  • Right handedness

Exclusion Criteria:

  • Concurrent severe infection
  • With other severe diseases
  • History of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc.
  • History of alcohol dependence and drug abuse
  • History of brain operation
  • Loss of vision or hearing
  • Psychotropic medication in three months
  • Contraindication of MRI examination, such as metal implants and claustrophobia, and other reasons that cannot cooperate with MRI examination
  • Cerebrovascular diseases which can be detected from conventional MR images, including the size of cerebral hemorrhage over 10 mm, infarction over 20 mm, subarachnoid hemorrhage, subdural hemorrhage and extradural hemorrhage.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Ming Zhang, PhD 0086-18991232265 zmmri@163.com
Contact: Shaohui Ma, MD 0086-15029215781 sh_ma@163.com
Listed Location Countries China
Removed Location Countries  
 
Administrative Information
NCT Number NCT03961724
Other Study ID Numbers XJTU1AF-CRF-2018-006
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party First Affiliated Hospital Xi'an Jiaotong University
Study Sponsor First Affiliated Hospital Xi'an Jiaotong University
Collaborators
  • NO.215 Hospital of Shaanxi Nuclear Industry
  • Baoji Zhongxin Hospital
  • Taihe Hospital
Investigators
Principal Investigator: Ming Zhang, PhD First Affiliated Hospital of Xian Jiaotong University
PRS Account First Affiliated Hospital Xi'an Jiaotong University
Verification Date April 2019